Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Melanoma 8Sarcoma 6Breast Neoplasms 4Triple Negative Breast Neoplasms 2Neoplasm Metastasis 2Carcinoma, Merkel Cell 2Skin Neoplasms 1Sarcoma, Kaposi 1Pleural Effusion, Malignant 1Peritoneal Neoplasms 1Pancreatic Neoplasms 1Neurofibromatosis 1 1Neurofibromatoses 1Neurofibroma 1Lymphoma, T-Cell, Cutaneous 1Lung Neoplasms 1Inflammatory Breast Neoplasms 1Hemangiosarcoma 1Carcinoma, Squamous Cell 1Carcinoma, Ductal, Breast 1Carcinoma, Ductal 1Carcinoma, Basal Cell 1Breast Carcinoma In Situ 1

Interventions

Paclitaxel 7Doxorubicin 5pembrolizumab 4pazopanib 4Gemcitabine 4Bevacizumab 4durvalumab 3Radiotherapy 3Propranolol 3Docetaxel 3regorafenib 2cemiplimab 2Surveys and Questionnaires 2Sunitinib 2Standard of Care 2Nivolumab 2Ifosfamide 23-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-f)indol-7-yl)-pyrrole-2,5-dione 2zanidatamab 1veliparib 1tucatinib 1trilaciclib 1tremelimumab 1trebananib 1trastuzumab duocarmazine 1talimogene laherparepvec 1talazoparib 1spartalizumab 1sintilimab 1selinexor 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Hemangiosarcoma × talimogene laherparepvec × Clear all
NCT03921073 2022-11-01

Study of T-VEC in Locally Advanced Cutaneous Angiosarcoma

H. Lee Moffitt Cancer Center and Research Institute

Phase 2 Terminated
5 enrolled 5 charts
Sarcoma

Hemangiosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡